Abstract: A rheology modifier for solvent-based coatings which is a polyacrylic acid or a poly(C.sub.1-4)-alkyl acrylic acid wherein at least 30% of the --COOH groups are converted to ester and/or amide groups. Preferred compounds are esters of polyacrylic acid where about 50% of the --COOH groups are esterified with a C.sub.4-12 -alcohol.

Abstract: A suspension of microcapsules in an organic liquid, the microcapsules containing an aqueous phase, is produced by interfacial polymerization in the presence of a proton transfer catalyst of a water-in-oil emulsion in which the aqueous phase contains a urea/formaldehyde or melamine/formaldehyde prepolymer.

Abstract: A stereoselective method for making compounds of Formula VIII ##STR1## wherein A and * are as defined in the specification. Enzymic processes and intermediates useful for preparing compound of Formula VIII are disclosed.

Abstract: The invention concerns a compound of formula (I), ##STR1## wherein, for example: R.sup.1 is of the formula --NHC(.dbd.O) (1-4C) alkyl; R.sup.2 and R.sup.3 are hydrogen or fluoro; R.sup.4 and R.sup.5 are hydrogen or methyl; >A--B-- is of the formula >C.dbd.CH--, >CHCH.sub.2, or >C(OH)CH.sub.2 -- (> represents two single bonds); D is O, S, SO, SO.sub.2 or --NR.sup.7 ; wherein R.sup.7 is hydrogen, R.sup.10 CO--, R.sup.10 SO.sub.2 --, R.sup.a OC(R.sup.b).dbd.CH(C.dbd.O)--, R.sup.c C(.dbd.O)C(.dbd.O)--, R.sup.d N.dbd.C(R.sup.e)C(.dbd.O)--, R.sup.f NHC(R.sup.g).dbd.CHC(.dbd.O)-- or R.sup.14 CH(R.sup.13)(CH.sub.2).sub.m --; wherein R.sup.10 is (1-6 C)alkyl [optionally substituted by, for example, hydroxy or (1-6 C)alkanoyl], R.sup.11 C(O)O(1-6 C)alkyl or R.sup.12 O--; wherein R.sup.11 is optionally substituted (1-6 C)alkyl; R.sup.12 is optionally substituted (1-6 C)alkyl; R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e, R.sup.f, R.sup.g are (1-6 C)alkyl; m is 0 or 1; R.sup.13 is cyano; R.sup.

Abstract: A low-foam, physically stable composition comprises (i) N-phosphonomethylglycine acid or a water-soluble salt thereof (ii) an alkylglycoside surfactant which is preferably 2-ethyl-1-hexyl glycoside having a degree of polymerization of from 1 to 2 and (iii) a quaternary ammonium salt surfactant such as a dialkyldimethylammonium salt wherein the sum of the carbon atoms in the dialkyl groups is from 12 to 20 or an alkyltrimethylammonium salt wherein the alkyl group contains from 4 to 12 carbon atoms.

Abstract: The invention provides isolated DNA sequences related to fruit ripening from muskmelon (Cucumis melo) having SEQ ID NO: 1 and SEQ ID NO: 2, or having a sequence which encodes the amino acid sequence encoded by SEQ ID NO: 1 or SEQ ID NO: 2. Also provided are DNA constructs, genetically modified plants and fruits containing the foregoing sequences, and methods of preparing genetically modified plants.

Abstract: The present invention concerns compounds according to the following formula, ##STR1## wherein: R.sup.1 is (CH.sub.2).sub.n,L where n is an integer in the range 0 to 6, and L is a carbon-linked five-membered heteroaryl ring having an oxygen or sulfur heteroatom, R.sup.4 is hydrogen, halo or NO.sub.2, and pharmaceutical compositions and methods of using thereof in the treatment and/or prevention of neurological diseases or conditions.

Abstract: Compounds antagonistic of the pain enhancing effects of prostaglandins are disclosed. The compounds comprise an optionally-substituted A ring with a --CH(R.sup.3)N(R.sup.2)B--R.sup.1 and --OD groups positioned in a 1,2 relationship to one another on ring carbon atoms. The 3-position ring-atom is not substituted. B is also an optionally-substituted ring and the group R.sup.1 is positioned on B in a 1,3 or 1,4 relationship with the --CH(R.sup.3)N(R.sup.2)-- linking group. R.sup.1, R.sup.2 and R.sup.3 and D can be a number of different organic or halogen moieties. N-oxides of --NR.sup.2 and S-oxides of sulphur containing rings are disclosed as are processes for the preparation of the compounds, intermediates in their preparation, pharmaceutical compositions containing them, and their use as therapeutic agents.

Abstract: Compounds and ink compositions. An ink composition comprising a compound of Formula (1) and salts thereof: ##STR1## wherein Ch represents an arrangement of atoms which causes the compound to absorb electromagnetic radiation;R.sup.a and R.sup.b each independently is a spacer group;Y is an interactive functional group;w and x each independently is 0 or an integer equal to or greater than 1; andm and n each independently is an integer equal to or greater than 1, provided that w and x are not both equal to zero and when one of w or x is 0 at least one of m and n is equal to or greater than 2. For use in ink jet printing and electrophotography.

Abstract: A process for preparing 4,6-dihydroxypyrimidine comprising the steps:a) contacting formamide, an alkoxide of formula ROM and a malonate of formula CH.sub.2 (CO.sub.2 R).sub.2 in a solvent of formula ROH;b) adding water to the product of step (a);c) removing substantially all of the solvent of formula ROH from the product of step (b); andd) acidifying the product of step (c)wherein R is C.sub.1-4 alkyl and M is an alkali metal.

Abstract: An isolated and purified human protein activator of apoptosis is described. A cDNA sequence which encodes the native kinase of death is disclosed as well as the structural coding region and the amino acid residue sequence. Methods are provided which employ the sequences to identify compounds that modulate the biological and/or pharmacological activity of the activator and hence regulate apoptosis. Biologically-effective antisense molecules, as well as dominant negative mutant versions of the apoptosis activator are described which are suitable for therapeutic use. The invention is also drawn toward the study, prevention, diagnosis, and treatment of pathophysiological disorders related to apoptosis.

Abstract: This invention concerns heterocyclic derivatives which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence in lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in diseases and medical conditions such as hypercholesterolemia and atherosclerosis.

Abstract: A compound of formula (I): ##STR1## wherein Ar is optionally substituted phenyl or optionally substituted 5-or 6-membered heterocyclic ring containing from 1 to 3 heteroatoms individually selected from nitrogen, oxygen and sulfur atoms, and at least one unsaturation (double bond) between adjacent atoms in the ring, said heterocyclic ring being optionally fused to a benzene ring; or an acid addition salt, quaternary ammonium salt or N-oxide derived therefrom, an insecticidal, acaricidal or nematicidal composition comprising a compound of formula (I) and a suitable carrier or diluent therefor, a method of combating and controlling insect, acarine or nematode pests at a locus which comprises treating the pests or the locus of the pests with an effective amount of a compound of formula (I) or a composition as hereinbefore described.

Abstract: Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists Substance P and NKA, useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein G, T.sup.1, T.sup.2 and T.sup.3 are selected from CH and N; provided that T.sup.2 and T.sup.3 are not both CH; A is selected from a direct bond and (1-4C)alkylene; X is selected from oxy, thio, sulphinyl, sulphonyl, carbonyl, carbonylamino, N-di-(1-6C)alkylcarbonylamino, sulphonamido, methylene, (1-4C)alkylmethylene and di-(1-6C)alkylmethylene, and when T.sup.2 is CH, X may also be selected from aminosulphonyl and oxycarbonyl; and Q is selected from (5-7C)cycloalkyl, a heterocyclic moiety containing up to 4 heteroatoms selected from nitrogen, oxygen and sulphur, phenyl, naphthyl, phenyl(1-4C)alkyl and phenyl(2-6C)alkenyl; for the manufacture of a medicament for treating diseases or medical conditions in which an inhibition of oxido-squalene cyclase is desirable.

Abstract: A compound of the Formula (1) and salts thereof: ##STR1## wherein: M is a metal or hydrogen;Pc is a phthalocyanine nucleus;R.sup.1 and R.sup.2 are each independently H or optionally substituted alkyl, aryl or aralkyl;R.sup.3 is an aminoalkyl group;L is a divalent organic linking group;x and y each independently have a value of 0.5 to 3.5; and(x+y) is from 3 to 4.A process for making the compounds of Formula (1). The compounds of Formula (1) are useful as colorants for inks which are used in for example ink jet printing of substrates such as paper, plastics, textile materials, metal or glass.

Abstract: Human E3 ubiquitin protein ligase is described. A structural region which encodes the polypeptide is disclosed as well as the the amino acid residue sequence of the protein ligase. Methods are provided which employ the sequences to identify compounds that modulate a biological and/or pharmacological activity of the molecule and hence regulate cellular and tissue physiology. The invention is also drawn toward the diagnosis, prevention, and treatment of pathophysiological disorders mediated by E3 ubiquitin protein ligases.

Abstract: A granule suitable for aqueous spray application after tank mix dispersion or dissolution comprises an active ingredient or auxiliary agent, an inert filler and a water-swellable material wherein the water-swellable material is incorporated into the granule in a substantially dry form. Preferred water-swellable materials are non-ionic or predominantly non-ionic and an especially preferred water-swellable material is Xantham gum. The granules provide reduced sludge residues in the spray tank and are particularly well suited for use when housed in a water-soluble bag.

Abstract: A process for preparing a compound of Formula (3) in which R.sup.2 is --H; ##STR1## which comprises the steps: i) conversion of a compound of Formula (1) into a compound of Formula (2) using a dioxygenase enzyme; ##STR2## ii) conversion of the compound of Formula (2) into a compound of Formula (3) wherein is --COR; andiii) conversion of the compound of Formula (3) in which R.sup.2 is --COR into a compound of Formula (3) in which R.sup.2 is --H;wherein R.sup.2, a, b, c, d, Z, m and X are as defined in claim 1.Also claimed are individual steps of the process and new compounds of Formula (2).

Abstract: The invention concerns pharmaceutically useful peptide derivatives of the formula (I): P--R.sup.1 --R.sup.2 --R.sup.3 --R.sup.4, in which P, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 have the various meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell mediated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.